Vivos (RDGL) Change In Receivables : $0.00 Mil (TTM As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is Vivos Change In Receivables?

Vivos's change in receivables for the quarter that ended in Mar. 2025 was $0.00 Mil. It means Vivos's Accounts Receivable declined by $0.00 Mil from Dec. 2024 to Mar. 2025 .

Vivos's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.00 Mil. It means Vivos's Accounts Receivable increased by $0.00 Mil from Dec. 2023 to Dec. 2024 .

Vivos's Accounts Receivable for the quarter that ended in Mar. 2025 was $0.01 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vivos's Days Sales Outstanding for the three months ended in Mar. 2025 was 30.42.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vivos's liquidation value for the three months ended in Mar. 2025 was $3.17 Mil.

Vivos Change In Receivables Historical Data

The historical data trend for Vivos's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Change In Receivables Chart

Vivos Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-0.01

Vivos Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Change In Receivables	Get a 7-Day Free Trial															-0.01	-	0.01	-0.01	-

Vivos Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Vivos (OTCPK:RDGL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vivos's Days Sales Outstanding for the quarter that ended in Mar. 2025 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.009	/	0.027	*	91
=	30.42

2. In Ben Graham's calculation of liquidation value, Vivos's accounts receivable are only considered to be worth 75% of book value:

Vivos's liquidation value for the quarter that ended in Mar. 2025 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3.265	-	0.115	+	0.75 * 0.009	+	0.5 * 0.021
=	3.17

Vivos Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vivos's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Inc (OTCPK:RDGL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 N Center Parkway, Kennewick, WA, USA, 99352

Website

https://www.radiogel.com

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.

Executives

Michael K Korenko	officer: INTERIM CEO AND PRESIDENT	6208 W OKANOGAN AVE, KENNEWICK WA 99336
Michael H Pollack	officer: Interim CFO	114 WEST 47TH STREET, 19TH FLOOR, NEW YORK NY 10036
Memorial Institute Battelle	10 percent owner	505 KING AVENUE, COLUMBUS OH 43201
Kenin M. Spivak	director	9663 SANTA MONICA BLVD., #1048, BEVERLY HILLS CA 90210
Thomas J Clement	director	12445 110TH LANE NE, APT. Q-302, KIRKLAND WA 98034
Leonard Bruce Jolliff	officer: Chief Financial Officer	206 N 41ST ST., UNIT 1, YAKIMA WA 98901
Cadwell Family Irrevocable Trust	10 percent owner	909 NORTH KELLOGG STREET, KENNEWICK WA 99336
James C Katzaroff	director, 10 percent owner, officer: CEO	719 JADWIN AVE., RICHLAND WA 99352
Bruce Wayne Ratchford	director, 10 percent owner	6208 W. OKANOGAN AVE., KENNEWICK WA 99336
Carlton M Cadwell	director, 10 percent owner	6208 W OKANOGAN AVE, KENNEWICK WA 99336